Capsugel expands early phase development and commercial manufacturing capabilities in Europe

Expansion and standardisation of offerings across the Capsugel network will help to serve customers in more locations

Capsugel, a global leader in delivering high quality, innovative dosage forms and solutions, has announced that it is expanding the technology platforms and capabilities at its product development and manufacturing sites in Edinburgh, UK, and Ploërmel and Strasbourg, France.

'We have taken several of Capsugel’s proprietary technology platforms that have demonstrated advantages with customer product development programmes and begun implementing them across multiple sites in our global network,' said Amit Patel, Sr Vice President and President, Dosage Forms, Capsugel.

'This expansion and standardisation of our offerings throughout our network allows us to better serve a wider range of customers in more locations, which can help them to accelerate speed to market, minimise costs and experience enhanced service levels.'

Early phase design: Capsugel is installing a proprietary spray drying unit at its Ploërmel facility later this year to complement the industry leading technology, expertise and formulation capabilities pioneered at its Bend, Oregon, facility in the US.

The company has also bolstered the Ploërmel facility’s microdosing service offering for early phase feasibility work with the addition of the latest generation of its proprietary Xcelodose 600S Precision Micro-Dosing System.

The system provides expanded capacity and industry leading powder-in-capsule expertise, leveraging the best practices established at Capsugel’s operations in Tampa, Florida, in the US. The company also plans to bring both its microdosing and spray drying technologies to its Edinburgh location in 2017.

Formulation R&D in live biotherapeutics: Live biotherapeutics, including the microbiome, represent a growing area of industry research and development. To meet the increasing number of customers that require this expertise, the company’s Strasbourg R&D facility, with specialised capabilities for the formulation of microbiome products, will open a new containment lab in the fourth quarter.

Manufacturing expansion: Expanded commercial manufacturing capacity for lipid-based formulations (LBF) using liquid fill hard capsules (LFHC), softgels or lipid multiparticulates is now online at Capsugel’s Edinburgh and Ploërmel sites.

Both facilities have expertise in manufacturing LBFs containing high-potency active pharmaceutical ingredients. LBF technologies are a key component in the company’s bioavailability enhancement offering.

Companies